-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] As a targeted chemotherapy drug, antibody-conjugated drugs have been expanded in recent years by many pharmaceutical compani.
Some data predict that from 2019 to 2024, the compound annual growth rate of the global antibody conjugated drug market will be 3
In 2022, the market size may reach 2 billion US dolla.
China's market size is expected to reach 2 billion US dolla.
In the face of the vast market, pharmaceutical companies have deploy.
It is reported that this year, a number of domestic antibody conjugated drugs have reached overseas licensing agreemen.
For example, on July 28, CSPC announced that its subsidiary CSPC Jushi Biology signed an exclusive licensing agreement with Elevation Oncology, and Elevation Company will obtain CSPC Jushi Bio's innovative anti-Claudin12 antibody-drug conjugate SYSA1801 in large-scale Development and commercialization rights outside of Chi.
The data show that in preclinical studies, SYSA1801 shows specific growth inhibitory activity against Claudin12 expressing cells in vitro, and has strong antitumor effects in vivo in mice implanted with gastric, pancreatic or lung cancer mode.
This product has been shown to be safe in rodents and non-human primat.
Under the terms of the agreement, CSPC Jushi Bio will receive an upfront payment of $27 million and is entitled to receive potential development and regulatory milestone payments of up to $148 million and potential sales milestone payments of up to $02 billi.
July 26 -- Colombo also announced that it has reached a cooperation and exclusive license agreement with Merck to develop an antibody conjugate (ADC) drug for the treatment of solid tumo.
According to the terms of the agreement, Colombo will exclusively license Merck to develop, manufacture and commercialize the ADC drug globally for a f.
The two parties will also collaborate on the early clinical development of the ADC dr.
According to the content of the agreement and the commercial development stage, Merck will pay Colombo Tech an upfront payment of US$35 million, various milestone payments of up to US$901 million and corresponding net sales commissio.
In addition, in May, Lixin Pharmaceutical reached an exclusive cooperation and licensing agreement with Turning Point in the United Stat.
According to the agreement, Turning Point will pay Lixin Pharma an upfront payment of US$25 million for the exclusive development and commercialization of a differentiated and innovative antibody-drug conjugate (ADC) LM-302 in countries and regions other than Greater China and South Korea righ.
According to public information, LM-302 is a Claudin 12 antibody-conjugated drug independently developed by Lixin Pharmaceutica.
It was approved by CDE on October 14, 202 It is currently undergoing Phase 1 for advanced solid tumor patients in China and the United Stat.
clinical tria.
It is understood that antibody-conjugated drugs (ADCs) have shown great potential for tumor treatment applications in recent years, and 14 drugs have been approved for marketing around the wor.
In order to better guide and promote the research and development of antibody conjugated drugs, CDE recently issued the "Technical Guidelines for Nonclinical Research of Antibody Conjugated Drugs (Draft for Comment)" and solicited opinio.
It expects to provide help and guidance for the non-clinical research of such dru.
The article points out that antibody-drug conjugates are a combination of biological macromolecules and small chemical molecules, with complex structural composition and functional characteristi.
Their non-clinical research should follow the general principles of innovative drug research and development, and at the same time comprehensively consider antibodies, linkers and small molecules in the dr.
The characteristics, indications, route of administration and administration schedule of molecular compounds and other factors adopt the evaluation strategy of specific analysis of specific proble.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Some data predict that from 2019 to 2024, the compound annual growth rate of the global antibody conjugated drug market will be 3
In 2022, the market size may reach 2 billion US dolla.
China's market size is expected to reach 2 billion US dolla.
In the face of the vast market, pharmaceutical companies have deploy.
It is reported that this year, a number of domestic antibody conjugated drugs have reached overseas licensing agreemen.
For example, on July 28, CSPC announced that its subsidiary CSPC Jushi Biology signed an exclusive licensing agreement with Elevation Oncology, and Elevation Company will obtain CSPC Jushi Bio's innovative anti-Claudin12 antibody-drug conjugate SYSA1801 in large-scale Development and commercialization rights outside of Chi.
The data show that in preclinical studies, SYSA1801 shows specific growth inhibitory activity against Claudin12 expressing cells in vitro, and has strong antitumor effects in vivo in mice implanted with gastric, pancreatic or lung cancer mode.
This product has been shown to be safe in rodents and non-human primat.
Under the terms of the agreement, CSPC Jushi Bio will receive an upfront payment of $27 million and is entitled to receive potential development and regulatory milestone payments of up to $148 million and potential sales milestone payments of up to $02 billi.
July 26 -- Colombo also announced that it has reached a cooperation and exclusive license agreement with Merck to develop an antibody conjugate (ADC) drug for the treatment of solid tumo.
According to the terms of the agreement, Colombo will exclusively license Merck to develop, manufacture and commercialize the ADC drug globally for a f.
The two parties will also collaborate on the early clinical development of the ADC dr.
According to the content of the agreement and the commercial development stage, Merck will pay Colombo Tech an upfront payment of US$35 million, various milestone payments of up to US$901 million and corresponding net sales commissio.
In addition, in May, Lixin Pharmaceutical reached an exclusive cooperation and licensing agreement with Turning Point in the United Stat.
According to the agreement, Turning Point will pay Lixin Pharma an upfront payment of US$25 million for the exclusive development and commercialization of a differentiated and innovative antibody-drug conjugate (ADC) LM-302 in countries and regions other than Greater China and South Korea righ.
According to public information, LM-302 is a Claudin 12 antibody-conjugated drug independently developed by Lixin Pharmaceutica.
It was approved by CDE on October 14, 202 It is currently undergoing Phase 1 for advanced solid tumor patients in China and the United Stat.
clinical tria.
It is understood that antibody-conjugated drugs (ADCs) have shown great potential for tumor treatment applications in recent years, and 14 drugs have been approved for marketing around the wor.
In order to better guide and promote the research and development of antibody conjugated drugs, CDE recently issued the "Technical Guidelines for Nonclinical Research of Antibody Conjugated Drugs (Draft for Comment)" and solicited opinio.
It expects to provide help and guidance for the non-clinical research of such dru.
The article points out that antibody-drug conjugates are a combination of biological macromolecules and small chemical molecules, with complex structural composition and functional characteristi.
Their non-clinical research should follow the general principles of innovative drug research and development, and at the same time comprehensively consider antibodies, linkers and small molecules in the dr.
The characteristics, indications, route of administration and administration schedule of molecular compounds and other factors adopt the evaluation strategy of specific analysis of specific proble.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
